Ridgewood Investments’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1,362
| Closed | -$52.3K | – | 397 |
|
|
2025
Q2 | $52.3K | Sell |
1,362
-5,050
| -79% | -$193K | 0.02% | 325 |
|
|
2025
Q1 | $191K | Buy |
6,412
+1,700
| +36% | +$62.2K | 0.09% | 184 |
|
|
2024
Q4 | $159K | Buy |
4,712
+1,350
| +40% | +$48.6K | 0.08% | 191 |
|
|
2024
Q3 | $137K | Sell |
3,362
-911
| -21% | -$37.3K | 0.07% | 207 |
|
|
2024
Q2 | $164K | Buy |
+4,273
| New | +$180K | 0.08% | 191 |
|
|
2024
Q1 | – | Sell |
-25,784
| Closed | -$956K | – | 213 |
|
|
2023
Q4 | $956K | Sell |
25,784
-1,814
| -7% | -$65.1K | 0.57% | 54 |
|
|
2023
Q3 | $1M | Sell |
27,598
-5,607
| -17% | -$199K | 0.66% | 48 |
|
|
2023
Q2 | $1.18M | Sell |
33,205
-930
| -3% | -$33.4K | 0.67% | 38 |
|
|
2023
Q1 | $1.21M | Sell |
34,135
-876
| -3% | -$30.6K | 0.74% | 30 |
|
|
2022
Q4 | $1.23M | Buy |
+35,011
| New | +$1.17M | 0.87% | 27 |
|
|
2022
Q3 | – | Sell |
-8,405
| Closed | -$457K | – | 182 |
|
|
2022
Q2 | $457K | Sell |
8,405
-1,587
| -16% | -$87.6K | 0.36% | 96 |
|
|
2022
Q1 | $544K | Sell |
9,992
-16,614
| -62% | -$902K | 0.36% | 95 |
|
|
2021
Q4 | $1.47M | Buy |
26,606
+7
| +0% | +$364 | 0.93% | 19 |
|
|
2021
Q3 | $1.27M | Sell |
26,599
-249
| -0.9% | -$12.5K | 0.86% | 24 |
|
|
2021
Q2 | $1.34M | Buy |
26,848
+2,882
| +12% | +$138K | 0.86% | 26 |
|
|
2021
Q1 | $1.07M | Buy |
23,966
+15,660
| +189% | +$711K | 0.65% | 48 |
|
|
2020
Q4 | $391K | Hold |
8,306
| – | – | 0.31% | 106 |
|
|
2020
Q3 | $391K | Sell |
8,306
-1,146
| -12% | -$57.4K | 0.31% | 107 |
|
|
2020
Q2 | $482K | Buy |
+9,452
| New | +$485K | 0.4% | 92 |
|
|
2019
Q4 | – | Sell |
-7,101
| Closed | -$379K | – | 202 |
|
|
2019
Q3 | $379K | Sell |
7,101
-360
| -5% | -$18.5K | 0.29% | 105 |
|
|
2019
Q2 | $373K | Buy |
7,461
+149
| +2% | +$7.48K | 0.29% | 111 |
|
|
2019
Q1 | $382K | Buy |
7,312
+788
| +12% | +$39.4K | 0.31% | 98 |
|
|
2018
Q4 | $328K | Hold |
6,524
| – | – | 0.26% | 110 |
|
|
2018
Q3 | $328K | Sell |
6,524
-200
| -3% | -$10.2K | 0.26% | 111 |
|
|
2018
Q2 | $339K | Sell |
6,724
-50
| -0.7% | -$2.52K | 0.3% | 104 |
|
|
2018
Q1 | $331K | Buy |
6,774
+528
| +8% | +$24.6K | 0.3% | 100 |
|
|
2017
Q4 | $277K | Buy |
6,246
+558
| +10% | +$25.8K | 0.25% | 117 |
|
|
2017
Q3 | $289K | Buy |
5,688
+1,158
| +26% | +$58.7K | 0.28% | 108 |
|
|
2017
Q2 | $244K | Buy |
4,530
+325
| +8% | +$17.3K | 0.24% | 117 |
|
|
2017
Q1 | $222K | Buy |
+4,205
| New | +$213K | 0.24% | 118 |
|
Other funds holding GSK
JEST
Ridgewood Investments's GSK Position: Q3 2025 in Review
Ridgewood Investments sold out of GSK (GSK) in Q3 2025, closing a stake of 1,362 shares — an estimated $52.3K sold.
Ridgewood Investments first reported a position in GSK in Q1 2017 and held it in 30 quarters. The position peaked at $1.47M in Q4 2021. 895 funds tracked by Wall St. Rank hold GSK as of Q3 2025.
- Ridgewood Investments reported no remaining GSK position as of Q3 2025 after selling out during the quarter.
- Ridgewood Investments sold 1,362 GSK shares in Q3 2025, an estimated $52.3K.
- Ridgewood Investments first reported a position in GSK in Q1 2017 and held it in 30 quarters.
- Ridgewood Investments's GSK position peaked at $1.47M in Q4 2021.
- 895 funds tracked by Wall St. Rank held GSK as of Q3 2025.
Based on Ridgewood Investments's 13F filing for Q3 2025, filed 30 Oct 2025.